Company Name: Cymabay Therapeutics Inc.
Cymabay Therapeutics Inc. is a clinical-stage biopharmaceutical company. The company is engaged in the development of therapies designed to treat metabolic (including orphan/rare) diseases. The company’s lead product candidate is designed to treat gout. The company’s pipeline includes product candidates for diabetes and mixed dyslipidemia.
Ticker Symbol: CBAY (NASDAQ)
Company Website: www.cymabay.com
Headquarters: Newark, CA